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Abstract
Methadone is a synthetic, long-acting opioid with a single chiral center forming two enantiomers, 
(R)-methadone and (S)-methadone, each having specific pharmacological actions. Concentrations 
of (R)- and (S)-methadone above therapeutic levels have the ability to cause serious, life-
threatening, and fatal side effects. This toxicity can be due in part to the pharmacogenetics of an 
individual, which influences the pharmacokinetic and pharmacodynamic properties of the drug. 
Methadone is primarily metabolized in the liver by cytochrome P450 (CYP) enzymes, 
predominately by CYP2B6, followed by CYP3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 
3A7, 2C8, 2C9, 3A5, and 1A2. Single nucleotide polymorphisms (SNPs) located within CYPs 
have the potential to play an important role in altering methadone metabolism and 
pharmacodynamics. Several SNPs in the CYP2B6, 3A4, 2C19, 2D6, and 3A5 genes result in 
increases in methadone plasma concentrations, decreased N-demethylation, and decreased 
methadone clearance. In particular, carriers of CYP2B6*6/*6 may have a greater risk for 
detrimental adverse effects, as methadone metabolism and clearance are diminished in these 
individuals. CYP2B6*4, on the other hand, has been observed to decrease plasma concentrations 
of methadone due to increased methadone clearance. The involvement, contribution, and 
understanding the role of SNPs in CYP2B6, and other CYP genes, in methadone metabolism can 
improve the therapeutic uses of methadone in patient outcome and the development of 
personalized medicine.
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1. Methadone pharmacology
Shortly after methadone was introduced in the United States, the Food and Drug 
Administration (FDA) approved its use as an analgesic and antitussive agent [1]. During the 
1960s, evidence for the usefulness of methadone in the treatment of and maintenance 
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therapy for narcotic addiction was growing [2,3]. A decade later, the FDA expanded the 
approval for physicians and hospital pharmacies to dispense methadone for treating opiate 
addiction in treatment programs only [1]. Enrollment in a methadone maintenance treatment 
(MMT) program also has the potential to be a public health strategy for decreasing the 
transmission of infectious diseases (e.g. HIV/AIDS, hepatitis C, or other blood-borne 
pathogens) by reducing the number of opioid users reusing contaminated needles [3–5].
Methadone is a synthetic, long-acting opioid with a single chiral center that forms two 
enantiomers, R-(−)-methadone (levo-methadone) and S-(+)-methadone (dextro-methadone) 
[6,7]. Both enantiomers have specific pharmacodynamic properties and pharmacological 
actions. (R)-Methadone is a μ-opioid receptor (MOR) agonist that mimics the body’s natural 
endogenous opioids, endorphins and enkephalins.Binding of (R)-methadone to the MOR 
mediates therapeutic effects with the release of other neurotransmitters, including 
acetylcholine, dopa-mine, norepinephrine, and substance P [6]. The effects propagated by 
this interaction yields reduction and elimination of drug cravings and withdrawal signs and 
symptoms of narcotics, analgesia, sedation, nausea, vomiting, constipation, miosis, 
antitussive effects, hypotension, mild bradycardia, and tolerance and dependence [8–11].
In the United States, methadone is clinically available only as a racemic formulation 
comprised of both (R)- and (S)-methadone enantiomers [12–14]. Methadone is currently 
used as: (1) an approved opioid substitution therapeutic agent to suppress opioid-abstinence 
syndrome in opiate abuse and addiction [15–19]; (2) a second-line opioid in alleviating 
cancer pain and chronic non-malignant pain, such as back, joint, or neuropathic pain and 
other forms of severe pain [20–23]; and (3) a first-line treatment in patients with both opioid 
dependence and chronic pain [24].
Methadone has contributed to a significant portion of opioid-related overdose deaths. 
However, this outcome is not attributed to the use of methadone for opioid dependence, 
rather from prescriptions of methadone for pain management [25]. Reports from the Centers 
for Disease Control and Prevention (CDC) indicate a 15.6% increase in opioid death rates 
from 2014 to 2015. Conversely, methadone death rates decreased by 9.1% due to factors 
such as efforts to reduce methadone therapy for pain, warning labels, clinical guidelines, and 
limiting high dose formulations [26]. However, death rates continued to increase through 
2014 resulting from methadone overdosing in individuals between the ages of 55–64 years 
[25].
Concentrations of (R)- and (S)-methadone above therapeutic levels have negative and 
detrimental side effects. Elevated (R)-methadone levels may depress ventilation, inducing 
respiratory depression, by acting on the MORs expressed on respiratory centers in the 
brainstem [27–29]. Conversely, an increase in (S)-methadone disposition causes 
cardiotoxicity through the blockage of the voltage-gated potassium channel of the human 
ether-a-go-go related gene (hERG), subsequently prolonging the QT interval of an 
electrocardiogram leading to torsades de pointes. (S)-Methadone is 3.5 times more potent 
than (R)-methadone in blocking the hERG channel, thus attributing the stereoselectivity of 
methadone to cardiotoxicity [30–33].
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Methadone is primarily eliminated via hepatic metabolism by cytochrome P450 (CYP) 
enzymes through oxidative biotransformation. Methadone undergoes stereoselective N-
demethylation followed by spontaneous cyclization to form the principle, inactive metabolite 
2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) (Fig. 1) [34–39].Methadone has a 
broad half-life of elimination ranging from 5 to 130 h, with an average of 22 h [40]. This 
extreme inconsistency in the elimination half-life exemplifies the large variability 
methadone possesses in its pharmacokinetics between individuals. Because of the inter-
individual variation, it is difficult to predict an individual’s peak plasma levels, which may 
result in some individuals having a higher than normal plasma level that approaches the 
toxic or even fatal drug concentration. Co-medication, age, gender, health, weight, and 
ethnicities can all be factors that contribute to this effect.
Genetic variation occurs within and among populations, leading to polymorphisms. Single 
nucleotide polymorphisms (SNPs) are the most common type of genetic variation. A SNP is 
a variation of a single nucleotide at a specific position in the genome, some of which may 
contribute to changes in a gene, either in the coding (exons) or non- coding (introns) regions, 
or the regions between genes. A genetic variation within CYP genes responsible for the 
metabolism of methadone may be causal for altered function, which may result in 
methadone being rapidly eliminated from the body, thus preventing the drug from reaching 
therapeutic levels. Alternatively, the genetic variation may prolong elimination from the 
body, consequently, intensifying analgesic and detrimental adverse effects [41,42]. The 
purpose of this review is to focus on the effects of SNPs of the various CYPs that metabolize 
methadone.
2. Methadone metabolism
Eleven metabolites from methadone metabolism have been isolated and identified in urine 
and feces in humans [43]. Methadone predominantly forms the pharmacologically inactive 
pyrrolidine metabolites EDDP and 2-ethyl-5-methyl-3,3-diphenylpyrroline (EMDP). 
Methadol and normethadol are active analgesic metabolites of methadone, although this 
pathway is relatively minor [44,45]. To a lesser extent, methadone, normethadol, EDDP, and 
EMDP are further hydroxylated to form inactive p-hydroxy metabolites. Another minor 
pathway yields the inactive metabolites 4-dimethylamino-2,2-diphenylvaleric acid, 4-
methylamino-2,2-diphenylvaleric acid, and 1,5-dimethyl-3,3-diphenyl-2-pyrrolidone (Fig. 1) 
[43–45].
The CYP enzymes involved in the formation of methadone meta-bolites in humans are 
CYP2B6, 3A4, 2C19, 2D6, and to a lesser extent, CYP2C18, 3A7, 2C8, 2C9, 3A5, and 1A2 
[46]. These CYPs, however, metabolize methadone in a stereoselective manner, where 
CYP2C19, 3A7, and 2C8 preferentially metabolize (R)-methadone, CYP2B6, 2D6, and 
2C18 primarily metabolize (S)-methadone, and CYP3A4 demonstrates no stereoselectivity 
in methadone metabolism [46,47]. Methadone is N-demethylated to an intermediate 
compound, normethadone, which is then spontaneously cyclized to form EDDP. A second 
N-demethylation reaction occurs on EDDP to form EMDP [35–37,44,48]. An alternate 
metabolic pathway in the formation of EMDP is a CYP mediated N-demethlyation of 
normethadone to form dinormethadone, which is then spontaneously cyclized to EMDP 
Ahmad et al. Page 3













[47]. In a minor bio-transformation pathway, the keto group of methadone is reduced by 
alcohol dehydrogenase to form methadol, which can be N-demethylated to form 
normethadol. The inactive (S)-methadone produces active metabolites of α-l-methadol and 
α-l-normethadol, which have analgesic properties comparable to (R)-methadone. (R)-
Methadone, on the other-hand, is metabolized to biologically inactive metabolites of d-
methadol and d-normethadol [44,45,47].
Methadone’s long ranging half-life can be partially attributed to the extreme interindividual 
pharmacokinetics and its stereoselective metabolism [49,50]. (S)-Methadone exhibits a 
significantly shorter elimination half-life than (R)-methadone [48,51]. Inherited 
polymorphisms in CYPs have the potential to affect the metabolic rate of methadone in a 
stereoselective manner. The following sections will discuss the role of CYP SNPs in 
methadone metabolism and its consequences on biological activity.
3. Cytochrome P450 (CYP)
There are approximately 57 active human CYP genes grouped into 18 families and 44 
subfamilies. Only 12 CYP enzymes, which belong to the CYP1, CYP2, or CYP3 families, 
are of major importance and responsible for the metabolism of more than 95% of therapeutic 
drugs [52–54]. The involvement and contribution of SNPs is inadequately understood in 
drug biotransformation, but are known to play a vital role in the differences in patient 
outcome and the development of personalized medicine [55]. SNPs can cause a loss of 
function mutation, in which the splicing, expression, or transcription of the CYP gene is 
decreased or the protein structure is altered. Alternatively, gain of function mutations may 
also occur, resulting in an increased substrate turnover due to an increased number of 
functional gene copies, as well as variations in the promotor or amino acids [54,56,57]. 
SNPs may be responsible for determining metabolic phenotype – ultra-rapid metabolizers 
(UMs), extensive metabolizers (EMs), intermediate metabolizers (IMs), and poor 
metabolizers (PMs) – and the binding affinity to CYPs, all while affecting the half-life, as 
well as the therapeutic and detrimental effects of methadone.
3.1. CYP1 family
The CYP1 family consists of two subfamilies, encompassing three functional genes, 
CYP1A1, 1A2, and 1B1. CYP1A1 and CYP1B1 enzymes are mainly expressed extra-
hepatically, whereas CYP1A2 accounts for 4–16% of the hepatic CYPs and is responsible 
for 8–10% of the drugs metabolized by CYP isoforms, including methadone [41,54,58].
The interindividual variations in the mRNA and protein expression levels of CYP1A2 range 
from 15 to 40 fold, and a 40–130 fold inter-individual difference in activity [59]. To date, 
there are 190 genetic variants in CYP1A2 [60,61]. An in silico study, by Wang et al. [52], 
found 31 nonsynonymous SNPs, of which 24 were predicted to be deleterious by the SIFT 
and PolyPhen algorithms. (S)-Methadone is marginally metabolized by CYP1A2 [46,62]. 
However, results of an in vitro study, conducted by Wang and DeVane [63], show neither the 
depletion of (R)- and (S)-methadone, nor the formation of EDDP by recombinant CYP1A2. 
Genetic variations in CYP1A2 did not affect or had little influence on the plasma 
concentrations of methadone and EDDP [22,46,59]. Additionally, Crettol et al. [64] 
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observed CYP1A2*1F did not influence (R)-, (S)-, or (R,S)-methadone at the peak or trough 
levels in 245 MMT patients (96% white) (Table 1). Based on the current studies, CYP1A2 
SNPs have not been shown to impact the metabolism of methadone.
3.2. CYP2 family
The CYP2 family represents about 30% of human CYP isoforms, making it the largest CYP 
family [65,66]. The liver is comprised of five drug metabolizing CYP2 subfamilies (A–E), 
of which, the most pharmacologically important genes display the highest levels of 
polymorphism [54,55]. Methadone is metabolized by several members of the CYP2 family: 
2B6, 2C8, 2C9, 2C18, 2C19, and 2D6.
3.2.1. CYP2B—CYP2B6 has a 1–10% contribution to the total hepatic CYP pool, 
accounting for the metabolism of about 7–8% of pharmaceutical drugs [54,59]. Despite this 
enzymes’ relatively low involvement in drug metabolism, CYP2B6 is the predominant 
determinant involved in the N-demethylation of methadone and clearance. CYP2B6 also 
displays stereoselectivity towards (S)-methadone [46,67]. CYP2B6 is one of the most 
polymorphic genes, having 70 allelic variants and 38 protein variants, which affect catalytic 
activity, transcriptional regulation, and splicing. The variants also affect mRNA and protein 
expression, exhibiting nearly 300 fold interindividual variability [54,60,68–71].
CYP2B6 SNPs can alter the metabolic ratios of [methadone]/[EDDP]. A significant decrease 
in the metabolic ratio was observed in individuals carrying the CYP2B6*2 allele, suggesting 
a role in an increased rate of metabolism. The data should be interpreted with caution 
because the subjects heterozygous for the variant only had a sample size of two [72]. A 
bioinformatics study also predicted CYP2B6*2 to alter the metabolic phenotype as 
determined by both the SIFT and PolyPhen algorithms [52].
Lee et al. [73] studied the influence of CYP2B6*4 on methadone plasma concentrations in 
178 MMT patients in Taiwan. The study indicated an increase in (R,S)-methadone plasma 
levels in individuals homozygous for CYP2B6*4. The results were consistent with the 
Levran et al. [74] study of 74 Israeli MMT patients; though neither study showed any 
significant differences in the increase in (R,S)-methadone plasma levels. On the other hand, 
Kharasch et al. [75] observed CYP2B6*4 carriers had a significant decrease in (R)-, (S)-, 
and (R,S)-methadone plasma levels, with increased methadone metabolism and clearance. It 
is important to note that one of the limitations to this study was the small sample size (n = 
4). Gadel and colleagues [76] demonstrated an increase in N-demethylation of methadone by 
CYP2B6*4 in an in vitro study, supporting the findings of Kharasch et al. [75].
CYP2B6*5 shows contradicting data in its involvement in methadone clearance and plasma 
concentrations. In a genotyping study of methadone-only overdoses in 125 Caucasians, 
CYP2B6*5 was linked to a significant increase in (R,S)-methadone plasma levels [72]. In a 
study cohort consisting of 35 individuals with low (S)-methadone levels, CYP2B6*5 was 
over-represented, indicating an increased CYP2B6 activity [32]. The methadone plasma 
concentration of two individuals genotyped for homozygosity in CYP2B6*5 appeared to 
remain unaltered when compared to that of the wild type CYP2B6*1 [75].
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CYP2B6*6 is a haplotype consisting of two nonsynonymous variants, CYP2B6*4 and 
CYP2B6*9. Numerous papers indicate an increase in (R,S)- and (S)-methadone plasma 
levels in CYP2B6*6/*6 individuals [64,67,75,77,78]. Gadel et al. [79] and Kharasch et al. 
[75] have also demonstrated a decrease in methadone N-demethylation and decreased 
methadone clearance, respectively. An in vitro study found SNPs CYP2B6*6 and 
CYP2B6*9 to be catalytically deficient in EDDP formation [76]. Furthermore, increased 
(R,S)-methadone plasma levels were observed in 74 Israeli MMT patients homozygous for 
the CYP2B6*9 SNP, though the increase was not statistically significant [74]. A significant 
increase in plasma concentrations and a decrease in (S)-methadone metabolism was 
observed in 366 Taiwanese MMT patients encompassing the CYP2B6*9 SNP [80]. The 
studies observing the SNPs of the haplotype CYP2B6*6 suggest that the diminishing 
metabolic activity of CYP2B6*6/*6 is credited to the c.516G > T variant of CYP2B6*9.
Dobrinas et al. [32] observed an overrepresentation of CYP2B6*11 polymorphism in a high 
(S)-methadone level group of MMT patients, indicating a decline in CYP2B6 activity. Wang 
et al. [80] examined polymorphisms in the intronic and 3′-untranslated region (UTR) 
regions of CYP2B6, and demonstrated the SNPs rs707265, rs2279345, rs1038376, and 
rs10403955 all correspond to increased [(S)-methadone/methadone dose] plasma ratios, and 
decreased (S)-methadone clearance (Table 1). The SNPs investigated in this section, 
demonstrate a compelling link to the importance of genetic variations in CYP2B6 and 
altered metabolism of methadone.
3.2.2. CYP2C—The CYP2C subfamily consists of four genes, CYP2C8, 2C9, 2C18, and 
2C19. The CYPs from these genes all contribute to the metabolism of methadone 
[46,77,81,82]. CYP2C9 is the highest expressed isozyme of the four in liver, while CYP2C8 
and CYP2C19 are expressed at 2 and 10 fold lower levels than CYP2C9 [54]. CYP2C18 is 
expressed primarily in the skin [59]. CYP2C19 comprises 16% of the CYP2C family and 
metabolizes methadone to a greater extent, as compared to the CYP2C8, 2C9, and 2C18 
isozymes [43]. The CYP2C family demonstrates stereoselectivity in methadone metabolism, 
where CYP2C8 and 2C19 predominately metabolize (R)-methadone, while CYP2C18 
primarily metabolizes (S)-methadone.
Currently, there are no polymorphic studies on CYP2C8 and 2C18 and their role in 
methadone metabolism. This is not surprising for CYP2C18, where only 8 variants have 
been reported to date [60,83]. There are 97 genetic variants observed in CYP2C8 [60,84], 
which has a minor role in the metabolism of methadone, probably contributing to the dearth 
of studies in the corresponding SNPs.
Although CYP2C9 exhibits 298 genetic variants and 2C19 has 111 reported genetic variants 
[60,85], only *2 and *3 have been examined for their respective CYP isozymes. Results 
from three separate studies showed no effect on methadone plasma levels with CYP2C9*2 
and CYP2C9*3 genotypes in Caucasians [64,77,82]. A significant increase in methadone 
serum concentrations/dose ratio with heterozygous carriers of CYP2C9*2 and CYP2C9*3 
SNPs was observed in a study in Norway. Similar results were seen for the homozygous 
CYP2C9*2 and CYP2C9*3 individuals, albeit, there was no significant differences in 
methadone serum concentrations/dose ratios [78].
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In studies by Crettol et al. [64,77], CYP2C19*2 and CYP2C19*3 were also found to lack an 
effect on methadone plasma levels. A study of 366 Taiwanese MMT patients showed 
homozygous carriers of CYP2C19*2 were associated with a significant increase in (R)-
methadone levels. Patients homozygous for CYP2C19*3 also tended to exhibit an increase 
in (R)-methadone levels, although the data was not significantly different [86]. Carlquist et 
al. [87] observed an increase in the plasma levels of EDDP with CYP2C19*2 in 25 MMT 
patients (20 Caucasian, 4 Hispanic, and 1 African American), indicating an increase in 
methadone metabolism. Kringen et al. [78] noticed, in a Norwegian population, individuals 
homozygous and heterozygous carriers for CYP2C19*2 and CYP2C19*3 had an increase in 
methadone serum concentration/dose ratio, with significant differences seen only in 
heterozygotes. The contradicting results in the CYP2C19 variants between these studies 
could be attributed to the ethnicity of the patients, where the frequencies of both 
CYP2C19*2 and CYP2C19*3 are higher in Asians than Caucasians (Table 1).
3.2.3. CYP2D—The CYP2D subfamily consists of only one protein coding 
gene,CYP2D6, which accounts for 2–5% of the hepatic CYP composition and ~25% of 
pharmacological drug metabolism [54,88]. CYP2D6 metabolizes both enantiomers of 
methadone, with a slightly greater propensity towards (S)-methadone [46,63]. Unlike SNPs 
in other CYP genes, CYP2D6 phenotype is determined by allele combinations. PMs consist 
of two non-functional alleles, IMs are comprised of two decreased activity alleles, EMs have 
at least one functional allele, and UMs encompass more than one functional allele and/or an 
allele with a promoter mutation [82]. The major and most common mutation alleles are 
CYP2D6*3, *4, *5, and *6, accounting for 93–97% of alleles among PM phenotypes 
[89,90]. CYP2D6*1 and CYP2D6*2 alleles represent normal functional activity.
In a 2001 study conducted by Eap et al. [89], CYP2D6 phenotypes had a significant 
influence on the (R)-, (S)-, and (R,S)-methadone blood concentrations, where higher 
concentrations were observed in PMs (CYP2D6*4/*4, *4/*3, *4/*6) and lower 
concentrations were measured in UMs (CYP2D6*1/*1). Similarly, Crettol and colleagues 
[64], observed a 0.5 fold decrease in (S)-methadone and 0.7 fold decrease in (R)-methadone 
plasma levels in UMs (CYP2D6*1/*1xN) when compared to the EM/IM (CYP2D6*1/*3, 
*1/*4, *1/*5, *1/*6) group. In another study, the PM, IM, and EM phenotypes, representing 
alleles CYP2D6*1, *1xN, *2, *3, *4, *4xN, *5, *6, *9, *10, *16, *28, *33, and *41, did not 
impact the clearance of (R)-, (S)-, or (R,S)-methadone [91]. CYP2D6*3, *4, *5, *6, *7, and 
*8 are non-functional variants, and CYP2D6*9, *10, and *41 have a decrease in function 
[91]. Fonseca et al. [82] observed EM patients received significantly lower doses of 
methadone as compared to UMs. It was also concluded that, contradictory to the 
phenotypes, UM (CYP2D6*1xN,*2xN) patients had significantly higher methadone plasma 
levels than EM (CYP2D6*1, *2, *3, *6, *35) and PM (CYP2D6*4/*4) patients. Further 
investigations on the CYP2D6 alleles need to be conducted to get a clearer understanding of 
their significance. The relationship between CYP2D6 allelic variants and phenotypic 
expression is depicted in Table 2.
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The CYP3 family consists of only one subfamily, CYP3A, and four functional genes, 
CYP3A4, 3A5, 3A7, and 3A43. These enzymes play a dominant role in drug metabolism 
pathways (~50%). CYP3A4 is the most expressed enzyme in adult liver, while CYP3A7 is 
predominantly expressed in fetal liver and is down-regulated after birth. CYP3A5 is 
polymorphically expressed in the liver, where alternative splicing results in multiple 
transcript variants, exhibiting high and low level proteins [54,88,92].
Methadone has been shown to be N-demethylated by CYP3A4, 3A5, and 3A7 in a non-
stereoselective manner [46,93]. CYP3A4 and CYP3A5 have relatively low numbers of 
genetic variants, suggesting minor clinical importance in the clearance of their respective 
substrates [59,74]. This observation would be in line with the lack of polymorphic studies 
found for CYP3A and their role in methadone metabolism. However, in one study, the allelic 
frequency of CYP3A4*1B in 245 MMT patients (96% white) was observed and correlated 
with an increase in methadone plasma levels [64]. In the same study, the study cohort was 
genotyped for the deficient allele CYP3A5*3. The plasma levels of methadone were not 
influenced by the CYP3A5 genotype. It is also interesting to note that there was a strong 
linkage between CYP3A4*1B and CYP3A5*3 genotypes [64]. Similar results were 
observed by Fonseca et al. [82], where the genetic polymorphism of CYP3A5 did not 
influence methadone plasma levels. One case report of a 25-year old male in a MMT 
program showed extensive metabolism of methadone to EDDP. The subject was found to be 
heterozygous for CYP3A5*1 (CYP3A5*1/*3) [94]. A large amount of CYP3A5 is 
expressed in individuals carrying at least one CYP3A5*1 allele [94]. In a recent study of 155 
serum samples and 62 patients, homozygous carriers of CYP3A5*3 demonstrated a 
significant increase in methadone serum concentration/dose ratio, indicating a decrease in 
methadone clearance [78] (Table 1).
4. Consequences of altered methadone metabolism
Polymorphisms in genes encoding CYP enzymes have the potential to shift their metabolic 
capacity or change the substrate specificity of the enzyme, eliciting variable consequences in 
drug treatment [95,96]. These changes can be crucial in the therapeutic potency of 
methadone. The main metabolic pathway of methadone involves the N-demethylation by 
hepatic CYPs into the primary metabolite, EDDP. Changes in the rate of EDDP formation 
could influence the pharmacodynamics of methadone.
CYP2B6*4 was the only SNP that was found to increase the clearance of methadone by the 
N-demethylation of both (R)- and (S)-methadone [75,76]. In turn, there would be a decrease 
in the disposition of (R,S)-methadone, reducing the pharmacological effect of methadone 
and inducing withdrawal symptoms. Individuals with this SNP may require a higher dose of 
methadone.
Several SNPs were found to increase the methadone plasma concentration due to a decrease 
in the metabolic activity of the CYPs. Three independent studies collectively demonstrated 
elevated plasma levels of (R,S)- and (S)-methadone with diminishing N-demethylation of 
(R)- and (S)-methadone due to CYP2B6*2, *9 and *11 [32,72,74,76,80]. CYP2B6*6 is a 
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haplotype consisting of both CYP2B6*4 and CYP2B6*9 variants. Carriers of CYP2B6*6/*6 
had diminished methadone metabolism and clearance, hence, an increase in methadone 
levels. This activity is credited to the CYP2B6*9 SNP, where individuals with 
CYP2B6*4/*6 haplotype did not observe the metabolic inhibition [64,67,75–79]. Mutations 
located in the UTR and intronic regions are also relevant in the biotransformation of 
methadone. Table 1 shows the four SNPs in the UTR and intronic regions linked to a 
decreased clearance and increased concentration of methadone [80]. CYP2B6 influences the 
metabolism of (S)-methadone and, to a far lesser extent,(R)-methadone. Individuals with the 
genotypes mentioned above, particularly CYP2B6*6/*6, have a greater risk of suffering 
torsades de pointes and sudden death. A lower dose of methadone may be required for 
treatment for individuals with these variants.
Reduced metabolism by CYP2C19 can lead to increased plasma concentrations of 
methadone, specifically (R)-methadone, which can potentiate depressed ventilation 
manifesting as a potentially fatal respiratory depression. Both CYP2C19*2 and CYP2C19*3 
were associated with elevated methadone plasma concentrations [78,86]. However, these 
results could be variable in different ethnic groups.
CYP2D6 and CYP3A4/5 metabolize both enantiomers of methadone, though CYP2D6 has a 
slightly greater preference towards (S)-methadone. Decreased metabolism by these CYPs 
may heighten either detrimental effect due to augmented levels of methadone. CYP3A4*1B 
has been shown to increase (S)-methadone plasma levels [64], which can lead to cardiotoxic 
effects. In a study of 136 Caucasian individuals who died of methadone-only overdosing, an 
enrichment was observed in the CYP3A4*1B SNP [97]. CYP3A5*3 is a common SNP with 
high frequency in the Caucasian population, where a splicing defect causes a loss of function 
of the CYP3A5 enzyme [58]. This is exemplified in a couple of studies where the 
methadone plasma levels are elevated in CYP3A5*3/*3 individuals, while metabolism is 
increased and plasma levels are decreased in individuals carrying at least one copy of 
CYP3A5*1 [79,94]. The effects of SNPs located on the CYP2D6 gene is slightly more 
complicated. CYP2D6-dependent metabolism of methadone has been studied based on the 
phenotypic variability determined by a combination of SNPs on the CYP2D6 gene. There 
have not been any clear implications on the relationship between CYP2D6 SNPs and 
methadone metabolism and their role on the pharmacokinetics and pharmacodynamics of 
methadone.
Since methadone is metabolized by a number of CYPs, a combination of any of the SNPs, 
within or between genes, can have varying effects on the pharmacological response of 
methadone treatment. A genome-wide pharmacogenomic study showed two CYP2B6 
haplotypes of rs8100458, rs7250601, rs7250991, rs11882424, rs8192719, and rs10853744 
(T-A-A-T-C-G and T-C-C-T-T-T) accounted for the variation in (S)-methadone plasma levels 
[98]. In order to understand the complexity of the effects of CYP SNPs on methadone 
pharmacokinetics and pharmacodynamics, inclusion of additional gene variants and haplo-
type variants is required. Though SNPs influence only part of methadone pharmacology, the 
impact of genetic variations can be compounded by drug interactions, environmental factors, 
sex, health, and other nongenetic factors. Co-administration of methadone with respiratory 
depressants, such as other opioids, alcohol, or benzodiaze-pines, may lead to a greater 
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detrimental effect. Likewise, individuals with reduced liver function (e.g. cirrhosis) could 
have a reduced capacity to metabolize methadone.
5. Conclusion
Methadone is currently used as a treatment and maintenance therapy for opioid addiction 
and as an analgesic for severe chronic pain. The wide-ranging half-life of methadone may 
result in some individuals having higher than normal therapeutic levels leading to negative, 
detrimental, and fatal side effects. Elevated (R)-methadone levels may lead to respiratory 
depression, while an increase in plasma levels of (S)-methadone may lead to severe cardiac 
arrhythmias. A significant portion of opioid-related deaths have been contributed to the use 
of prescription methadone for pain management. The pharmacogenetics of an individual 
possesses the ability to affect the pharmacokinetics and pharmacodynamics of methadone. 
SNPs located on CYP genes shift the metabolic capacity or change the substrate specificity 
of the CYP enzyme, affecting the metabolism of methadone. SNPs CYP2B6*6, *9, *11, 
CYP2C19*2, *3, CYP3A4*1B, and CYP3A5*3 result in increased methadone plasma 
concentrations, decreased N-demethylation, and decreased methadone clearance. Since 
CYP2B6 is the major determinant of methadone clearance, CYP2B6*6/*6 is of particular 
interest. Homozygous carriers of CYP2B6*6/*6 expressed diminished methadone 
metabolism and clearance, thus these individuals have a greater propensity for detrimental 
adverse effects. However, CYP2B6*4 demonstrated an increase in N-demethylation and 
methadone clearance. A better understanding of the role of CYP SNPs in methadone 
metabolism can improve the proper therapeutic dosing for methadone, patient outcome, and 
the development of individualized medicine.
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Eleven methadone metabolites found in human excretion. *Indicates chiral carbon atom. 
ADH, alcohol dehydrogenase; CYP, cytochrome P450; EDDP, 2-ethyl-1,5-dimethyl-3,3-
diphenylpyrrolidine; EMDP, 2-ethyl-5-methyl-3,3-diphenyl-1-pyrroline; p-HO, para-
hydroxy.
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Table 1
Cytochrome P450 single nucleotide polymorphisms relevant to methadone metabolism.




Effect on enzyme activity Ref.
CYP1A2*1F rs762551 intron 1, c.−9–154C > A
No influence on (R)-, (S)-, or 
(R,S)-MTD levels at trough or 
peak
[64]
CYP2B6*2 rs8192709 c.64C > T R22C ↑ [(R,S)-MTD]/[EDDP] ratio [72]
CYP2B6*4 rs2279343 c.785A > G K262R ↑ (R,S)-MTD plasma levels [73,74]
↓ (R,S)-MTD plasma levels [75,76]
↑ MTD clearance
↑ (R)- and (S)-MTD N-
demethylation
CYP2B6*5 rs3211371 c.1459C > T R487C ↓ (S)-MTD plasma levels [32]
↑ (S)-MTD clearance
No effect on MTD clearance [75]
↑ (R,S)-MTD plasma levels [72]
CYP2B6*6 rs2279343 c.785A > G K262R ↑ (S)- and (R,S)-MTD plasma levels [64,67,75–79]
rs3745274 c.516G > T Q172H ↑ MTD/Dose plasma ratio
↓ (R)- and (S)-MTD N-
demethylation
↓ MTD clearance
CYP2B6*9 rs3745274 c.516G > T Q172H ↑ (R,S)-MTD plasma levels [74,76,80]
↑ [(S)-MTD/MTD Dose] plasma 
ratio
↓ (R)- and (S)-MTD N-
demethylation
↓ (S)-MTD clearance
CYP2B6*11 rs35303484 c.136A > G M46V ↑ (S)-MTD plasma levels [32]
↓ (S)-MTD clearance
CYP2B6 3′UTR rs707265 c.*1355A > G ↑ [(S)-MTD/MTD Dose] plasma ratio [80]
↓ (S)-MTD clearance
CYP2B6 3′UTR rslO38376 3’UTR, c.*1277A > T ↑ [(S)-MTD/MTD Dose] plasma ratio [80]
↓ (S)-MTD clearance
CYP2B6 intron 1 rsl0403955 c.172–468 T > G ↑ [(S)-MTD/MTD Dose] plasma ratio [80]
↓ (S)-MTD clearance
CYP2B6 intron 5 rs2279345 c.923–197T > C ↑ [(S)-MTD/MTD Dose] plasma ratio [80]
↓ (S)-MTD clearance
CYP2C9*2 rsl799853 c.430C > T R144C No effect on MTD plasma levels [64,77,82]
↑ MTD/Dose plasma ratio [78]
CYP2C9*3 rsl057910 c.1075A > C I359L No effect on MTD plasma levels [64,77,82]
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Effect on enzyme activity Ref.
↑ MTD/Dose plasma ratio [78]
CYP2C19*2 rs4244285 c.681G > A I331V; splicing defect No effect on MTD plasma levels [64,77,82]
↑ (R)-MTD plasma levels [78,86]
↑ MTD/Dose plasma ratio
↑ EDDP plasma levels [87]
CYP2C19*3 rs4986893 c.636G > A W212X; stop codon No effect on MTD plasma levels [64,77]
↑ MTD/Dose plasma ratio [78]
CYP3A4*1B rs2740574 5’UTR, C,−392A > G ↑ (S)-MTD plasma levels [64]
CYP3A5*3 rs776746 5’UTR,c.219–237A > G Splicing defect No effect on MTD plasma levels [64,82]
↑ MTD metabolism [94]
(*1/*3 carrier)
↑ MTD/Dose plasma ratio 
(*3/*3) [78]
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee [69].
CYP, cytochrome P450; MTD, methadone; EDDP, 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolidine; UTR, untranslated region.
†
National Center for Biotechnology Information (NCBI) dbSNP [88].
‡
Location of sequence change on mRNA for the respective CYP NM accession number [88].
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Table 2









Effect on enzyme activity Phenotype Ref.
CYP2D6∗1 Wild type Duplication of gene EM [57,64,82,89,91]
CYP2D6∗lxN Multiduplication of gene UM [64,82,91]
N active genes
↑ activity
CYP2D6∗2 rsl6947 c.886C > T R296C Normal activity EM [57,82,89,91]
rsl 135840 c.1457G > C S486T Duplication of gene
CYP2D6∗2xN Multiduplication of gene UM [82]
N active genes
↑ activity
CYP2D6∗3 rs3574686 c.775delA 259Frameshift Defective allele PM [64,82,89,91]
CYP2D6∗4 rsl 065852 c.lOOC > T P34S Defective allele PM [57,64,82,89,91]
rs28371703 c.271C > A L91M
rs28371704 c.281A > G H94R
rs3892097 c.506–1G > A Splicing defect
rsl 135840 c.1457G > C S486T
CYP2D6∗4xN Defective allele Multiduplication of gene PM [91]
CYP2D6∗5 Deletion of entire CYP2D6 gene PM [57,64,91]
CYP2D6∗6 rs5030655 c.454delT 118Frameshift Defective allele PM [64,82,89,91]
CYP2D6∗7 rs5030867 c.971A > C H324P Defective allele PM [91]
CYP2D6∗8 rs5030865 c.505G > A G169R Defective allele PM [91]
rsl 6947 c.886C > T R296C
rsl 135840 c.1457G > C S486T
CYP2D6∗9 rs5030656 c.841_843delAAG K281del Impaired function IM [91]
CYP2D6∗10 rsl 065852 c.lOOC > T P34C Impaired function IM [57,91]






CYP2D6H∗17 rs28371706 c.320C > T T107I Impaired function IM [57]
rsl 6947 c.886C > T R296C
rsl 135840 c.1457G > C S486T
CYP2D6∗28 rs78482768 19G > A V7M Unknown Unknown [91]
rsl 6947 c.451C > G Q151E
rsl 135840 c.886C > T R296C
c.1457G > C S486T
CYP2D6∗29 rs61736512 c.406G > A V136I Impaired function IM [57]
rsl 6947 c.886C > T R296C






















Effect on enzyme activity Phenotype Ref.
rs59421388 c.1012G > A V338M
rsl 135840 c.1457G > C S486T
CYP2D6∗33 rs28371717 c.709G > T A237S Normal activity EM [91]
CYP2D6∗35 rs769258 c.31G > A V11M Normal activity EM [57,82]
rsl 6947 c.886C > T R296C Duplication of gene
rsl 135840 c.1457G > C S486T
CYP2D6∗36 rsl 065852 c.lOOC > T P34S Defective allele PM [57]
rsl 135840 c.1457G > C S486T
CYP2D6∗41 rsl 6947 c.886C > T R296C Impaired function IM [91]
rs28371725 c.985 + 39G > A Splicing defect
rsl 135840 c.1457G > C S486T
CYP2D6∗43 rs28371696 c.77G > A R26H Normal activity EM [57]
Duplication of gene
CYP2D6∗45 rs28371710 c.463G > A E155K Normal activity EM [57]
rsl 6947 c.886C > T R296C Duplication of gene
rsl 135840 c.1457G > C S486T
More comprehensive information is available from the Human Cytochrome P450 Allele Nomenclature Committee [69].
CYP, cytochrome P450; del, deletion; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer; UM, ultra-rapid 
metabolizer.
†
National Center for Biotechnology Information (NCBI) dbSNP [88].
‡
Location of sequence change on mRNA for the respective CYP NM accession number [88].
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